CD Bioparticles announces the launch of its new line of Cellulose Nanoparticles. NEW YORK, NY, UNITED STATES, February 21, 2025 /EINPresswire ...

Genprex advances diabetes programme with addition of research focused on non-viral delivery system: Austin, Texas Thursday, February 20, 2025, 16:00 Hrs [IST] Genprex, Inc., a cli ...

A two-and-a-half-year-old girl shows no signs of a rare genetic disorder, after becoming the first person to be treated for ...

Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...

IntroductionNeglected Tropical Diseases (NTDs) remain a significant health burden in tropical and subtropical regions, with limited treatment options ...

Genprex (GNPX) announced the advancement of its diabetes program through a strategic collaboration with a contract development and ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

A new lipid nanoparticle system can deliver messenger RNA (mRNA) to the brain via intravenous injection. | Drug Discovery And ...

The Mt. Sinai study could open the door to future therapies for Alzheimer’s, amyotrophic lateral sclerosis, brain cancer, and ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual ...